Antibacterial Activity of the Novel Drug Gepotidacin against <i>Stenotrophomonas maltophilia</i>—An In Vitro and In Vivo Study

<i>Stenotrophomonas maltophilia</i> is increasingly recognized as a nosocomial bacterial pathogen with a multi-drug resistance profile. In this study, the novel drug gepotidacin, the first compound of the novel triazaacenaphthylene topoisomerase inhibitor antibiotics class, was evaluated...

詳細記述

書誌詳細

出版年:	Antibiotics
主要な著者:	Maike Isabell Sanders, Eyhab Ali, Jan Buer, Joerg Steinmann, Peter-Michael Rath, Hedda Luise Verhasselt, Lisa Kirchhoff
フォーマット:	論文
言語:	英語
出版事項:	MDPI AG 2022-02-01
主題:	<i>Stenotrophomonas maltophilia</i> gepotidacin triazaacenaphthylene topoisomerase inhibitor <i>Galleria mellonella</i> cystic fibrosis
オンライン･アクセス:	https://www.mdpi.com/2079-6382/11/2/192